Plerixafor Injection Market Segmentation:
- By Type
- Prefilled Syringe
- Injectable
- Lyophilized
- By Hematopoietic Stem Cell Transplantation Type
- Autologous
- Allogeneic
- By End-user
- Hospitals
- Specialty Clinics
- Stem Cell Banks
- Others
- By Combination Therapy
- Plerixafor + GCSF
- Plerixafor + Chemo + GCSF
- Others
- By Application
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Hodgkin’s Lymphoma
- Acute Myeloid Leukemia
- Others
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
The current market size is USD 580 million in 2024.
Rising prevalence of blood cancers, growth of stem cell transplantation procedures globally, entry of biosimilars, and technology advancements.
High costs of treatment, low awareness levels in developing regions, complex regulatory pathways for new products.
The prefilled syringe segment accounts for over 40% share owing to ease of administration.
Genzyme Corporation, Sanofi, Cadila Healthcare, Mylan N.V., Dr Reddy's Laboratories, Cipla Ltd., among others.
The market is projected to grow at a CAGR of 7.2% to reach USD 1,011.5 million by 2031.
Increasing blood cancer incidence, rising stem cell transplantations, new product launches, and growth in developed regions like North America.